model updat rais pt
up lt assumpt
updat model explicit project shown
exhibit slightli lower sale estim cc
cc organ report cc cc organ
report vs consensu report guidanc rang
ep estim remain unchang
in-lin consensu guidanc rang model gm/
om/cash tax rate unchang pt goe
prior remain buy rate
updat estim fy sales/ep estim
cc cc organ
cc cc organ estim compar
consensu within manag
guidanc rang decreas revenu
mostli due neg fx impact slightli off-set higher endoscopi
intervent cardiolog urolog pelvic health model
assum gm/om/cash tax rate unchang base
pipelin market opportun outlin recent endoscopi analyst
meet rais long-term estim franchis
may prove conserv
look call
approach offer wsj link although
respons unlik us watchman momentum believ laa closur
terrif opportun link product momentum spectra
acur tavr ex-u ep portfolio inclus directsens
updat new product launch includ acur europ
system design statu singl use duodenoscop
exalt comment recent acquisit financi expect
claret medic cerebr embol protect tavr cryterion medic
cryoablat balloon emcis endolumin surgeri gi cancer
surgeri
continu pg
tr target
enrol progress manag hf trial heartlog pinnacl flx watchman flx accur
updat lotu us launch re-entry ou market
valuat risk new pt deriv rel valuat framework
regress year top-lin expect rel forward multipl larger cap med tech
compani period revenu forecast show compound-annual-growth-rate think
reason assum anoth point inorgan growth contribut given bsx like improv
posit beyond suggest rel forward multipl multipli
market multipl around yield target forward multipl multipli
estim ep month henc arriv pt upsid
potenti current price support thesi bsx track record commit
margin improv irrespect acquisit relat dilut risk includ greater anticip
decay bsx histor slow growth market less model growth buoyant franchis
 structur heart ep neuromodul medsurg acquisit misstep
page
page
page
page
milion except per share busi rate incom ep pre-tax tax rate net margin ex incom cc organ ex-endochoic forma corpor
boston scientif corp develop manufactur market medic devic use diagnos
treat medic condit heart digest pulmonari vascular urolog women health chronic
pain found john abel pete michael nichola headquart
success diversifi away prior depend slow growth icd/pacer/
stent market cc top-lin project like augment
increment inorgan growth cash balanc constraint allevi align
compani guidanc regard oper margin take comfort bsx
steadi track record deliv margin aggreg revenu project in-lin
consensu like diverg detail due somewhat higher expect intra-cardiac monitor
electrophysiolog ep spinal cord stimul deep brain stimul perhap watchman
slightli lower expect tavr think endoscopi urological/pelv health franchis
perform consist cusp enter sever interest adjac
new form bph treatment ovarian cancer diagnosi endolumin colo-rect surgeri
valuat risk
pt deriv rel valuat framework regress year top-lin
expect rel forward multipl larger cap med tech compani period
revenu forecast show compound-annual-growth-rate think reason assum anoth
point inorgan growth contribut given bsx like improv posit beyond
suggest rel forward multipl multipli market multipl
around yield target forward multipl multipli estim ep
month henc arriv pt upsid potenti current price
support thesi bsx track record commit margin improv irrespect
acquisit relat dilut risk rate price target includ greater anticip decay
bsx histor slow growth market less model growth buoyant franchis
structur heart ep neuromodul medsurg acquisit misstep
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
